Company profile

PFE stock data

(
)

Calendar

6 Aug 20
14 Aug 20
31 Dec 20

News

Company financial data Financial data

Quarter (USD) Jun 20 Mar 20 Sep 19 Jun 19
Revenue 11.8B 12.03B 12.68B 13.26B
Net income 3.43B 3.41B 7.68B 5.06B
Diluted EPS 0.61 0.61 1.36 0.89
Net profit margin 29.10% 28.35% 60.60% 38.12%
Operating income* 4.32B 4.27B 11.13B 4.52B
Net change in cash -350M -634M 1B -153M
Cash on hand 1.8B 2.15B 2.79B 1.78B
Cost of revenue 2.28B 2.38B 2.6B 2.58B
Annual (USD) Dec 18 Dec 17 Dec 16 Dec 15
Revenue 53.65B 52.55B 52.82B 48.85B
Net income 11.19B 21.36B 7.25B 6.99B
Diluted EPS 1.87 3.52 1.17 1.11
Net profit margin 20.85% 40.64% 13.72% 14.30%
Operating income* 13.17B 13.53B 9.51B 10.14B
Net change in cash -203M -1.25B -1.05B 298M
Cash on hand 1.14B 1.34B 2.6B 3.64B
Cost of revenue 11.25B 11.23B 12.32B 9.65B

Financial data from Pfizer earnings reports. *Asterisk values are approximate.

Date Owner Security Transaction Code 10b5-1 $Price #Shares $Value #Remaining
6 Aug 20 Blaylock Ronald E Common Stock Buy Aquire P No 38.62 1,000 38.62K 13,000
6 Aug 20 Blaylock Ronald E Common Stock Buy Aquire P No 38.69 1,000 38.69K 12,000
6 Aug 20 Blaylock Ronald E Common Stock Buy Aquire P No 38.51 1,500 57.77K 11,000
6 Aug 20 Blaylock Ronald E Common Stock Buy Aquire P No 38.56 2,500 96.4K 9,500
6 Aug 20 Blaylock Ronald E Common Stock Buy Aquire P No 38.55 3,000 115.65K 7,000
6 Aug 20 Blaylock Ronald E Common Stock Buy Aquire P No 38.49 4,000 153.96K 4,000
31 Jul 20 Albert Bourla Phantom Stock Units SSP Common Stock Grant Aquire A No 38.48 13 500.24 78,470
31 Jul 20 John D Young Phantom Stock Units SSP Common Stock Grant Aquire A No 38.48 11 423.28 47,212
31 Jul 20 Rady A Johnson Phantom Stock Units SSP Common Stock Grant Aquire A No 38.48 4 153.92 5,619
70.4% owned by funds/institutions
13F holders
Current Prev Q Change
Total holders 2369 2465 -3.9%
Opened positions 115 292 -60.6%
Closed positions 211 108 +95.4%
Increased positions 963 989 -2.6%
Reduced positions 1091 942 +15.8%
13F shares
Current Prev Q Change
Total value 1.38T 1.49T -7.2%
Total shares 3.91B 3.99B -1.9%
Total puts 34.5M 28.95M +19.2%
Total calls 24.3M 25.65M -5.3%
Total put/call ratio 1.4 1.1 +25.8%
Largest owners
Shares Value Change
Vanguard 461.98M $15.08B +2.7%
BLK BlackRock 424.07M $13.84B -0.5%
STT State Street 292.62M $9.55B +0.3%
Capital World Investors 224.81M $7.34B +19.1%
Wellington Management 218.68M $7.14B +12.9%
Geode Capital Management 89.95M $2.93B +1.0%
BAC Bank of America 86.67M $2.83B -12.4%
NTRS Northern Trust 70.02M $2.29B -1.6%
State Farm Mutual Automobile Insurance 56.54M $1.85B 0.0%
BK Bank of New York Mellon 56.09M $1.83B -6.2%
Largest transactions
Shares Bought/sold Change
Norges Bank 0 -59.37M EXIT
Fisher Asset Management 5.45M -39.93M -88.0%
Capital World Investors 224.81M +36.09M +19.1%
Wellington Management 218.68M +24.95M +12.9%
Capital International Investors 8.22M -13.78M -62.6%
Massachusetts Financial Services 39.2M -12.62M -24.4%
BAC Bank of America 86.67M -12.24M -12.4%
Vanguard 461.98M +12.02M +2.7%
GS Goldman Sachs 33.13M -11.45M -25.7%
Renaissance Technologies 2.6M -10.5M -80.1%
Content analysis ?
Positive
Negative
Uncertain
Constraining
Legalese
Litigous
Readability
H.S. freshman Avg
New words: AAH, adapted, addressing, Adjuvant, Agent, Albert, automatically, besylate, blinded, Bourla, BRIGHT, broadly, chose, cohort, Cortexyme, cyber, daunorubicin, deeply, Diflucan, dispense, dispensed, dispensing, ehf, England, epidemiological, faith, febrile, fewer, futility, glycoprotein, GmbH, good, gradual, gradually, guarantor, heard, hearing, inconsistent, insulin, intermediary, journal, lifesaving, Lightspeed, loan, London, malware, manifested, maternal, meningococcal, mentioned, messenger, Mexico, misrepresented, mobility, myelosuppressive, Neisseria, Neratinib, neuropathic, neutralizing, neutropenia, NHS, notice, Nyvepria, partnership, peer, phishing, precedent, preclinical, pregabalin, proven, PTC, Puma, RAR, ready, Reddy, regimen, RET, RNA, RSV, safe, sampling, schedule, Scotland, Scottish, SE, Shanghai, shorter, skin, spike, statutory, steady, syncytial, Trump, UK, unconditionally, unnecessary, vitro, withdrawn, young, Zoloft
Removed: acute, aged, alectinib, ALK, Amneal, amyloid, artificially, Authorisation, autonomy, Avastin, Avillion, azacitidine, Baxter, begin, Ben, bevacizumab, Biotech, capture, cardiovascular, catch, category, Celltrion, ceritinib, cervical, CMA, comprised, consistently, crizotinib, culture, declared, Eurohealth, familial, fine, Genentech, germline, Gland, glioblastoma, Hengrui, Hikma, HR, induction, informed, Janssen, Jiangsu, Kabi, leaving, letter, Lorviqua, media, meglumine, modest, monotherapy, myeloid, NDA, neck, negotiating, Orion, OTC, output, overturned, persistent, pertaining, phenytoin, PLC, polyneuropathy, Precedex, premix, recurrent, retain, saline, Sarl, setting, sodium, solution, spinoff, split, susceptibility, TKI, Tribunal, unresectable, vaccinated, Venue, voluntarily, write, Zirabev